P-selectin glycoprotein ligand-l (PSGL-1) is a mucin-like glycoprotein ligand for P-and E-selectin on myeloid cells and a subset of lymphocytes. We used flow cytometry and immunohistochemistry t o examine expression of PSGL-1 on minor leukocyte populations, differentiating hematopoietic cells, and nonhematopoietic tissues using t w o monoclonal antibodies t o distinct protein epitopes on PSGL-1. In the bone marrow, PSGL-1 was expressed on myeloid cells from the myeloblast stage to the segmented neutrophil, but was not detected on erythroblasts or megakaryocytes. All types of circulating myeloid cells expressed PSGL-1, and PSGL-1 was retained after extravasation of myeloid cells into tissues. PSGL-1 was also expressed on circulating dendritic cells, monocyte-derived dendritic cells, dendritic cells in lymphoid tissues and epidermis, and follicular dendritic -SELECTIN glycoprotein ligand-1 (PSGL-1) is a sialomucin ligand for P-selectin that was originally identified in human neutrophils and the promyelocytic cell line HL-60.' PSGL-I mediates adhesion of neutrophils to P-selectin under static conditions and rolling of neutrophils on P-selectin under flow conditions in vitro and in vivo.'.' In addition, leukocyte PSGL-1 functions cooperatively with Lselectin to mediate optimal attachment of flowing neutrophils to E-selectin in vitro.4
cells. All types of lymphoid cells examined expressed PSGL-1, including immature and mature thymocytes, naive and memory T cells, y/S T cells, natural killer cells, B cells, and CD34+ progenitor cells. However, PSGL-1 levels were substantially lower on tonsillar lymphocytes than on circulating lymphocytes, suggesting that PSGL-1 expression is downregulated during or after entry of lymphocytes into secondary lymphoid tissue. Although PSGL-1 antigen was detected primarily on hematopoietic cells, it was also present on the epithelium of the fallopian tube. Furthermore, PSGL-1 antigen was detected sporadically on microvascular endothelium in some pathologic tissues. This suggests that PSGL-1 may have functions other than mediating leukocyte adhesion.
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selectin recognition, whereas the N-linked glycans are not required.
Immunofluorescence staining of peripheral blood leukocytes with anti-PSGL-l monoclonal antibodies (MoAbs) indicates that most lymphocytes, like myeloid cells, express the PSGL-1 polypeptide.2 However, only a small fraction (010% to 20%) of lymphocytes bind P-selectin with high affinity/dvidity.2.'','4 P-selectin binding to this subset of lymphocytes is abolished by an MoAb to PSGL-1, indicating that PSGL-l is the predominant P-selectin ligand on these cells.' Thus, most peripheral blood lymphocytes do not express PSGL-I in a form that can bind P-selectin. The functional heterogeneity of PSGL-1 on lymphocytes may be due to differential expression of glycosyltransferases andor sulfotransferases that direct posttranslational modifications of PSGL-1 that are required for optimal P-selectin recognition.
It is unclear whether PSGL-I is expressed by minor subpopulations of myeloid and lymphoid leukocytes and whether the level of PSGL-1 expression varies between leukocyte subsets. In addition, it is not known whether PSGL-1 expression is regulated during differentiation of hematopoietic cells or whether PSGL-l is present in nonhematopoietic tissues. We report here a detailed flow cytometric and immunohistochemical analysis of the distribution of PSGL-1 antigen in hematopoietic and nonhematopoietic tissues, using MoAbs that recognize protein-dependent epitopes on human PSGL-1. We found that PSGL-1 was primarily restricted to cells of hematopoietic origin in normal human tissues. It was broadly expressed on differentiating and mature cells in the myeloid, lymphoid, and dendritic lineage. PSGL-I antigen was also detected on the epithelial lining of the fallopian tube and on microvascular endothelium in some pathologic tissues, but not in a variety of other nonhematopoietic tissues.
$6-1, and IgG, were purchased from Becton Dickinson (San Jose, CA). FTTC-CD3 (UCHTI) and FITC-CD22 (RFB4) were purchased from Ancell (Bayport, MN). OKT3 (CD3, IgG%) hybridoma supernatant was a gift from Dr Linda Thompson (Oklahoma Medical Research Foundation, Oklahoma City, OK). Control mouse IgG, -K (MOPC21) was from Cappell-Organon Teknika (Durham, NC) and UCHL-1 (CD45R0, IgGh) was from Dako (Carpinteria, CA). All MoAbs used were IgG, -K unless otherwise indicated. Phycoerythrinstreptavidin (PE-SA) was from Molecular Probes (Eugene, OR). FITC-goat antimouse IgGngM F(ab'), was purchased from CappellOrganon Teknika and FITC-goat antimouse Ig was from Fisher Scientific (Pittsburgh, PA). FITC-goat antimouse IgG, and PE-goat antimouse IgGz, were from Caltag (South San Francisco, CA).
Cell lines. The human cell lines CCRF-CEM, MOLT-4, HUT-78, HL-60, U-937, THP-1, K562, Jurkat, Ramos, and Daudi were obtained from the American Type Culture Collection and maintained in RPMI 1640/10% fetal calf serum (FCS) at 37°C and 5% COz.
Cell isolation. Heparinized blood was obtained from healthy donors according to protocols approved by the Institutional Review Board of the University of Oklahoma Health Sciences Center or the Human Use Committee of Duke University Medical Center. Granulocytes were isolated by dextran sedimentation, hypotonic lysis, and density gradient centrifugation on Histopaque-IO77 (Sigma, St Louis, MO), as described.'* Granulocyte fractions were greater than 90% neutrophils by Wright-Giemsa staining and greater than 90% CD16' as assessed by flow cytometry. Eosinophils were isolated from granulocytes by negative immunomagnetic selection with CD16 Microbeads using the Magnetic Cell Separation System (Miltenyi Biotec, Auburn, CA).I9 Eosinophil preparations were greater than 95% pure by Wright-Giemsa staining and greater than 95% CD16-as assessed by flow cytometry. Mononuclear cells (MNCs) were isolated from peripheral blood and from samples of cytopheresis products procured from patients undergoing peripheral blood stem cell collections (Oklahoma Blood Institute, Oklahoma City, OK) by density gradient centrifugation on Histopaque-1077. T cells (>95% CD3') were purified from MNCs by rosetting with sheep erythrocytes (Ferrell Farms, McCloud, OK) at 29T, as described." Tonsillar MNCs (68% t 2% CD22' and 27% t 2% CD3' [mean ? SDI, n = 3) were isolated from fresh tonsils of patients undergoing tonsillectomy for recurrent tonsillitis. Cryopreserved human thymocytes were a gift from Dr Haroldine Stafford (University of Oklahoma Health Sciences Center, Oklahoma City, OK). Fresh thymus obtained from children undergoing cardiac surgery was gently teased apart and the released cells were washed with cold RPMI 1640/10% calf serum and then subjected to density gradient centrifugation on Histopaque-1077. The MNCs were collected, washed with cold RPM1 1640/10% calf serum, resuspended in a mixture of 55% RPMI 1640 with 20% glucose/45% dimethylsulfoxide, and frozen in liquid NZ.
A dendritic cell-enriched population of cells was isolated from whole blood or buffy coats (North Carolina Red Cross, Durham, NC), as previously described with some modifications. 16 Briefly, MNCs were isolated by density gradient centrifugation on FicollPaque (Pharmacia, Piscataway, NJ). The MNCs were depleted of T cells by sheep erythrocyte rosetting and the T-cell-depleted MNCs were cultured overnight at 37°C in 100-mm tissue culture plates, with two subsequent 30-minute culture periods at 37°C in fresh culture plates to remove residual monocytes. The remaining nonadherent MNCs were resuspended at 5 X lo6 cells/mL and layered onto hypertonic 14.5% metrizamide (Sigma) in 15-mL conical centrifuge tubes and sedimented at 650s for 15 minutes at room temperature. A dendritic cell-enriched population was harvested from the interface of the metrizamide gradient.
Dendritic cells were also generated from CD14+ blood monocytes." Monocytes were isolated from blood MNCs by plastic adherence, as described. 16 Monocytes were recovered by incubation in cold saline for 20 minutes at 4°C. Resuspended monocytes (5 X IO6 cells/mL) were layered onto hypertonic 14.5% metrizamide and centrifuged at 6508 for 15 minutes at room temperature to sediment contaminating lymphocytes. Cells (>98% CD14+) were harvested from the interface of the metrizamide gradient and resuspended ( lo6 cells/mL) in RPMI 1640/10% fetal calf serum, IO m o V L glutamine, and penicillitdstreptomycin. Monocytes were cultured for 5 days in 6-well tissue culture plates (IO6 cells/mL) in medium containing granulocyte-macrophage colony-stimulating factor (GM-CSF; 800 U/mL) and interleukin-4 (IL-4; 500 U/mL; Genzyme, Cambridge, MA). The cultures were fed with fresh media and cytokines on day 3. On day 5, the cultures were fed with fresh medium containing GM-CSF (800 U/mL), IL-4 (500 U/mL), and tumor necrosis factora (TNF-a; 100 U/mL; Genzyme). The dendritic cells generated from these cultures were harvested 3 days later and were greater than 80% CD83' when examined by immunofluorescence staining.
Flow cytometry. For indirect immunofluorescence staining, cells were washed with ice-cold Hank's balanced salt solution (HBSS) containing 1% FCS and 0.1% NaN3. The cells were incubated with each MoAb as either hybridoma supernatant or purified MoAb at concentrations optimal for immunostaining. In certain experiments, the primary MoAb was directly FITC-conjugated, PE-conjugated, or biotinylated. Bound primary MoAb was detected using the appropriate FITC-or PE-conjugated secondary antibody. When biotinylated primary MoAb was used, bound antibody was detected with PE-SA. Each incubation was for 30 minutes at 4°C in HBSS/l% FCS/O. 1 % NaN,, between which the cells were washed with HBSSI 1% FCS/O.l% NaN,. After the last wash, the cells were fixed with 1% paraformaldehyde in HBSS. Four-parameter list mode data were acquired using a Becton Dickinson FACScan flow cytometer. Binding of purified platelet P-selectin to cells was examined as previously described.* Tissue specimens. Normal tissues were obtained from either normal portions of surgical specimens or from autopsy specimens at University Hospital and Children's Hospital of the University of Oklahoma Health Sciences Center and were procured according to institutional guidelines. Tissues were fixed in 10% paraformaldehyde, processed, paraffin-embedded, and sectioned using conventional techniques. Snap-frozen lymph nodes and tonsils were used to evaluate possible antigen loss when studying paraformaldehydefixed, paraffin-embedded tissues. Air-dried peripheral blood and bone marrow smears were also examined.
Immunohistochemistry. Deparaffinized sections were treated with 1.25% H202 in methanol for 30 minutes to block endogenous peroxidase activity. Slides were microwave pretreated as previously described," with minor modifications, in 10 mmoVL citrate, pH 6.0, for 5 minutes in a 700-W microwave oven set at 50% power. The slides were allowed to cool for 20 minutes at room temperature. Immunohistochemical staining for PSGL-I antigen was performed using standardized avidin biotin peroxidase methodology. The slides were incubated with phosphate-buffered saline (PBS) containing 10% horse serum to inhibit nonspecific antibody binding, followed by primary antibody diluted in PBS/l% bovine serum albumin for 60 minutes. The working concentrations of the PLI and PL2 MoAbs were 2 pg/mL and 1.5 pg/mL, respectively. An irrelevant mouse monoclonal IgG, MoAb (Bethyl Laboratories Inc, Montgomery, TX) was used at equivalent concentrations. Biotin-conjugated horse antimouse secondary antibody was applied for 20 minutes, followed by Vectastain Elite ABC reagent (Vector Laboratories, Burlingame, CA) for 30 minutes. Diaminobenzidine (Sigma) or 3-amino-9-ethylcarbazole (BioGenex, San Ramon, CA) was used as a chromogen. Hematoxylin was used for nuclear counterstaining. Between incubation steps, the slides were washed with PBS. All steps were performed at room temperature.
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The same procedure was used for frozen sections and for bone marrow and peripheral blood smears, except that the slides were fixed in acetone at -20°C for 10 minutes and no microwave pretreatment was used. For immunostaining with the UCHL-l MoAb, no microwave pretreatment was used.
Unless indicated, immunohistochemical analyses were performed on three different specimens of each tissue examined. All tissues were separately stained with the PLl MoAb and the PL2 MoAb. In every case, indistinguishable staining patterns were observed with each antibody.
RESULTS
Binding of the anti-PSGL-I MoAbs PLI and PL2 is not affected by posttranslational mod$cations of the PSGL-l polypeptide. PLl and PL2 are IgG, MoAbs that bind to independent epitopes on human PSGL-1.2.23 Cells can express only one isoform of PSGL-l because the entire coding region is encoded by a single exon of the PSGL-1 gene.6 Several lines of evidence indicate that PL1 and PL2 recognize protein-dependent epitopes that do not appear to be influenced by posttranslational modifications. The PL1 and PL2 epitopes have been mapped to two distinct linear peptides using bacterially expressed fusion proteins and synthetic peptide.23 PL1 binds to a single epitope spanning residues 49 through 62 and PL2 binds to an epitope within residues 188 through 255 of PSGL-1. Thus, PL1 and PL2 bind to PSGL-1 that lack glycosylation and tyrosine sulfation, because bacteria lack the biosynthetic machinery to perform these posttranslational modifications. The MoAbs bind to recombinant PSGL-1 expressed in Chinese hamster ovary (CHO) cells that lack endogenous fucosyltransferase and core 2 GlcNAc transferase activity.' Binding of PL1 and PL2 to PSGL-l on CH0 cells is not affected by coexpression of three different fucosyltransferases (FucTIII, FucTIV, or FucTVII) and/or the core 2 GlcNAc transferase.12 Sialidase treatment of neutrophils or purified PSGL-l under conditions that abolish binding of an anti-sialyl Lewis' MoAb (CSLEX-1) does not affect MoAb recognition (data not shown). These observations indicate that recognition of PSGL-l by PL1 and PL2 is not affected by the presence or absence of tyrosine sulfation, sialylation, fucosylation, or branched 0-linked oligosaccharides on PSGL-1. Therefore, these MoAbs appear to be useful probes for detecting the PSGL-1 polypeptide in different cell types.
PSGL-I expression on peripheral blood leukocytes and hematopoietic cell lines.
Neutrophils and monocytes are known to express PSGL-1 .' To determine if eosinophils expressed PSGL-l, these cells were purified (>95% pure) and analyzed in parallel with neutrophils (>90% pure) from the same donors. Figure 1 (left panels) shows that greater than 95% of eosinophils and neutrophils bound both PL1 and PL2. The background-subtracted mean fluorescence intensity of eosinophils and neutrophils stained with PL1 (1 18 2 22 U 110 2 15 [mean -t SDI, n = 3) and PL2 (66 t 17 U 55 2 6 [mean 2 SDI, n = 3) were not significantly different.
Specific surface staining of eosinophils with PL1 and PL2 was also confirmed by immunohistochemistry (see Fig 4A) . We next examined if PSGL-l on eosinophils functioned as a ligand for P-selectin. Eosinophils, like neutrophils, bound platelet P-selectin (Fig l, right panels) . Binding of P-selectin to eosinophils and neutrophils was abolished by PLl, but not by PL2. Thus, PSGL-1 accounts for all the high-affinity binding sites for P-selectin on human eosinophils as well as on neutrophils. ' To directly determine which lymphocyte populations expressed PSGL-1 antigen and to compare the relative levels of PSGL-1 expression on these cells, peripheral blood MNCs were stained with biotin-PL2 and FITC-conjugated MoAbs directed against CD3, CD16, CD19, or the y/6 T-cell receptor, followed by PE-SA. Virtually all T cells (CD3'), natural killer (NK) cells (CD16+), and B cells (CD19') expressed PSGL-I (Fig 2A) . However, CD19' lymphocytes expressed relatively low levels of PSGL-1. All $6 T cells expressed PSGL-l at levels comparable to those on total T cells and NK cells (data not shown).
The uniformity of anti-PSGL-l MoAb binding to CD3' lymphocytes suggested that both naive (CD45RO-) and memory (CD45RO') T cells expressed comparable levels of PSGL-1. To directly examine this possibility, CD3' cord blood lymphocytes were analyzed. In three independent analyses, CD3' lymphocytes from normal adult donors (1 1 % to 30% CD45RA') and cord blood (>90% CD45RA') bound comparable levels of PL1 and PL2, as assessed by flow cytometry (data not shown). These results indicate that memory and naive T cells express comparable levels of the PSGL-1 polypeptide. Cord blood granulocytes and monocytes, like those from adults, were also uniformly positive for PLl and PL2 binding (data not shown).
To determine whether CD34' progenitor cells expressed the PSGL-1, we analyzed samples of peripheral blood stem cell collections using two-color flow cytometry. We found that circulating CD34' progenitor cells expressed the PSGL-1 polypeptide, but at lower levels than did CD34-cells ( Fig  2B) .
Severa1 human hematopoietic cell lines were also analyzed ( Table 1 ). All myeloid and T-cell lines examined bound both PLI and PL2. Of the two B-cell lines examined, Daudi cells bound PL1 and PL2 weakly, whereas Ramos cells did not bind either MoAb.
PSGL-l expression on dendritic lineage cells. A dendritic cell-enriched, metrizamide low-density fraction of blood MNCs was isolated to determine whether circulating dendritic cells express the PSGL-1 polypeptide. Dendritic cells were identified by their selective expression of CD83.I5.l6 The vast majority of blood CD83' cells expressed significant levels of PSGL-l, as detected by the PL1 and PL2 MoAbs (Fig 3A, left panel) . The CD83' cells expressed PSGL-1 at levels comparable to the CD14+ monocytes present in the metrizamide low-density fraction (data not shown). Functionally mature dendritic cells can also be generated from CD14' blood monocytes after culture with GM-CSF, IL-4, and TNF-a." These cells are morphologically, phenotypically, and functionally similar to dermal dendritic cells, which may be precursors of circulating dendritic cells. Like circulating CD83+ dendritic cells, the vast majority of monocyte-derived CD83' dendritic cells expressed PSGL-1 at levels comparable to their monocyte precursors, as detected by the PLl and PL2 MoAbs (Fig 3B, left panel) .
We next examined if PSGL-l on dendritic cells functioned 
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as a ligand for P-selectin. Both blood-and monocyte-derived CD83+ dendritic cells bound platelet P-selectin (Fig 3A and  B , right panels). P-selectin binding was specific in that it was blocked by the anti-PSGL-l MoAb PL1, but not by PL2. However, blood dendritic cells bound P-selectin less efficiently than did monocyte-derived dendritic cells analyzed in parallel. The percentage of CD83' monocyte-derived dendritic cells that bound P-selectin varied between cultures from -60% to greater than 95% (data not shown).
These results indicate that PSGL-1 accounts for all the highaffinity binding sites for P-selectin on dendritic cells. PSGL-1 expression in bone marrow. To assess at which stages of myeloid differentiation the PSGL-1 polypeptide was expressed, normal bone marrow was analyzed by immunohistochemistry. PSGL-1 was detected on myeloid cells at all stages of maturation from the myeloblast to the segmented neutrophil (Fig 4B and C) . The percentage of positive cells was estimated by scoring PSGL-1 staining in 30 to 100 myeloid cells at each stage of maturation in bone marrow smears from five normal patients. PL1 strongly stained 68% rt 3% of myeloblast and promyelocytes, 86% rt 2% of myelocytes, and 100% of metamyelocytes, bands, and segmented neutrophils (mean ? SD, n = 5). Similar results were obtained using PL2. PL1 and PL2 also bound to maturing eosinophilic granulocytes. Neither MoAb bound to erythroblasts or megakaryocytes (Fig 4B and C) . This finding is consistent with previous observations that PL1 or
Control +PL1
I I 1 1 1 1 1 1~ I I I 1 1 1 1 1~ I I 1 I I n P-selectin-PE + P-selectin-PE + PL2 did not bind to circulating erythrocytes or platelets? We also observed that PLl and PL2 bound to myeloblasts from patients with acute myelogenous leukemia (FrenchAmerican-British [FABI-M1 and M2) and chronic myelogenous leukemia in myeloid blast transformation (data not shown).
PSGL-I expression in lymphoid tissues. Immunohistochemical analysis of lymph nodes (Fig 4D) and tonsils (data not shown) showed that PSGL-1 immunoreactivity was primarily restricted to the T-cell zones. PL1 and PL2 reacted strongly with interdigitating reticulum dendritic cells (IRDCs) that were distinguished by their typical morphology and distribution. The majority of the lymphocytes in the Tcell zones showed little or no immunoreactivity. In contrast, control experiments showed that UCHL-1, an MoAb to CD45RO on memory T cells, strongly stained a high proportion of the lymphocytes in the T-cell zones (Fig 4F) . Most of the cells in the mantle zones and the germinal centers of secondary follicles were PSGL-l negative (Fig 4D and E) . However, foilicular dendritic cells (FDCs) in germinal centers showed moderate to strong surface staining (Fig 4E) . Lymphocytes and polymorphonuclear leukocytes within the subcapsular sinuses showed strong PSGL-1 immunoreactivity, and the subcapsular sinus-lining cells were moderately stained. High endothelial venules did not stain with either PL1 or PL2. Similar results were obtained when snap-frozen tonsils and lymph nodes were analyzed, indicating that the
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In paraffin-embedded fetal thymus (1 1 and 38 weeks of gestational age), PSGL-1 immunoreactivity was primarily restricted to the medulla (Fig 4H) , in which the most prominently stained cells had the characteristic morphology of IRDCs and a distribution similar to that previously observed for CD83 staining.'? In addition, macrophages in both the cortex and medulla showed strong PSGL-I staining. Approximately 10% of cortical and medullary thymocytes showed mildly positive PSGL-1 staining. Medullary and cortical epithelial cells were negative.
Cryopreserved, thawed human thymocytes were isolated from infants ( < I 2 months of age) to determine whether these cells expressed the PSGL-1 polypeptide. Cortical and medullary thymocytes were identified by the absence or presence of CD3 staining, respectively. The thymocytes analyzed were 40% to 64% CD3' (n = 4). Most thymocytes expressed significant levels of PSGL-1 antigen, as detected by the PL 1 (data not shown) and PL2 MoAbs (Fig 6A) . Immature CD3 -/IOW thymocytes and mature CD3' thymocytes expressed comparable levels of PSGL-I antigen, as detected by the PL2 MoAb. Parallel analyses of blood MNCs indicated that peripheral blood T cells expressed PSGL-1 antigen at threefold to fourfold higher levels than did thymocytes (Fig 6B) .
A variety of normal human tissues were surveyed for PSGL-1 antigen by immunohistochemistry ( Table 2 ). The only normal nonhematopoietic tissue that consistently stained with both PL1 and PL2 was the fallopian tube epithelium ( Fig  7A) . In a variety of other tissues, PSGL-I antigen was not detected on the predominant parenchymal cell. However, in many tissues, the MoAbs stained eXtraVaSCUlar mOnOnUCkar and polymorphonuclear leukocytes. Strong PSGL-1 staining was observed on Kuppfer cells in the liver ( F ,~ 7~) and on large bowel (Fig 7c) . Interestingly, lymphoid aggregates in the intestinal submucosa showed little or no staining. In the PSGL-I expression in nonhematopoietic tissues. 
MoAb ( P E ) and FITC-conjugated control IgGr mTC-CD3, FITC-CD19.
macrophages in the mucOSa of the stomach and of small and lack of T-cell immunoreactivity was not due to antigen loss as a consequence of tissue fixation and/or preparation.
The minimal PSGL-1 immunoreactivity of lymphocytes in the T-cell zone of the tonsil and lymph node contrasts with the uniform positivity of T cells in peripheral blood. Therefore, we used flow cytometry to directly compare the level of PSGL-1 antigen expression on lymphocytes from tonsils and peripheral blood. We observed that PSGL-1 expression on lymphocytes from tonsils was lower than on lymphocytes from peripheral blood analyzed in parallel ( Fig  5) . The background-subtracted mean fluorescence intensity of PL2 staining on lymphocytes from tonsil and blood was 1.4 +. 0.6 and 3.9 2 0.3, respectively, for CD22+ cells, and 7.8 2 1.6 and 25.3 2 3.0, respectively, for CD22-cells (mean ? SD, n = 3).
In the spleen, some perifollicular T cells showed mild to moderate PSGL-1 immunoreactivity. Follicular lymphocytes were negative, but FDCs were focally positive. Macrophages and mature myeloid cells within the red pulp were strongly positive (Fig 4G) . (Fig 7D) . In the lung, PL1 strongly stained polymorphonuclear leukocytes in capillaries and alveolar macrophages (Fig 7E) . Type I1 pneumocytes were negative. In various part of the brain, no detectable parenchymal PSGL-1 staining was observed, including microglial cells (Fig 7F) . PSGL-I expression in parhologic tissues. Some randomly selected pathologic tissues were also examined for PSGL-l antigen. Strong staining of intravascular and extravascular polymorphonuclear leukocytes was observed in tissues with acute inflammation (Fig 7G) . Some small venules and capillaries in certain pathologic tissues also exhibited lumenal staining with the anti-PSGL-l MoAbs. These tissues included benign hyperplasia of the prostate (Fig 7H) and fibrocystic disease of the breast. In contrast, staining of vascular endothelium was not detected in normal tissues or in tissues undergoing acute inflammation. In fibrocystic disease of the breast, some cysts were also stained.
DISCUSSION
Previous work has established that most leukocytes in peripheral blood express PSGL-l.* However, it was unclear whether this was true of minor subpopulations of myeloid and lymphoid leukocytes. In addition, PSGL-1 expression on cells of dendritic lineage has not been examined. FurthermAb-FITC + P-selectin-PE + more, it was not known whether PSGL-1 expression was regulated during differentiation of hematopoietic cells or whether PSGL-1 expression was restricted to cells of hematopoietic origin. To examine these questions, we performed a detailed flow cytometric and immunohistochemical analysis of PSGL-1 expression in human cells and tissues, using two MoAbs directed against distinct protein-dependent epitopes on PSGL-1.
We found that PSGL-1 was expressed on CD34+ progenitor cells in peripheral blood. PSGL-l was also expressed on myeloid cells in the bone marrow at all stages of maturation from the myeloblast to the segmented neutrophil, but was not detected on erythroblasts and megakaryocytes. CD34' hematopoietic progenitor cells have been shown to bind to immobilized P-selectin and to P-selectin expressed by activated platelet^.*^*^^ These cells also synthesize PSGL-1 mRNA.24 Although surface expression of PSGL-1 was not shown in these studies, adhesion of hematopoietic progenitors to P-selectin was shear resistant, Ca2+-dependent, and sialidase and protease sensitive, features that are consistent with PSGL-1 -dependent adhesion. Multipotential colonyforming cells (CFU-Mix), their precursors (pre-CFU), and cells committed to myeloid (CFU-granulocyte-macrophage [CFU-GM]) and erythroid (burst-forming unit-erythroid [BFU-E]) differentiation were enriched by panning on Pselectin. However, more mature glycophorin A+ bone marrow erythroid cells were not enriched by panning on P- For personal use only. on November 11, 2017. by guest www.bloodjournal.org From (-) Paraffin-embedded tissues were analyzed by immunohistochemistry using the anti-PSGL-l MoAbs PL1 or PL2 as described in the Materials and Methods.
* The presence (+l or absence (k) of staining of parenchymal cells t Both secretory and proliferative endometrium were examined, in the indicated tissue.
eosinophils bound P-selectin and that binding was abolished by the anti-PSGL-1 MoAb PL1, but not by PL2. These results indicate that PSGL-1 is the predominant high-affinity ligand for P-selectin on eosinophils and on other myeloid leukocytes. This finding is consistent with previous observations that adhesion of eosinophils to P-selectin was sensitive to sialidase and protease treatment of the cells.26 Symon et ally showed that P-selectin on the apical surface of endothelium in nasal polyps mediated adhesion of eosinophils. These observations suggest that PSGL-I may mediate adhesion of eosinophils to P-selectin at sites of allergic inflammation.
LASZIK ET AL
Strong PSGL-1 staining was observed on both intravascular and extravascular neutrophils at sites of acute inflammation and on macrophages in a variety of tissues. Thus, PSGL-1 was retained on myeloid cells after emigration into tissues in vivo. This i s consistent with previous observations that PSGL-I expression does not decrease after neutrophil activation in vitro, although it is redistributed to the uropod of the activated Taken together, our findings indicate that myeloid cells express PSGL-l throughout differentiation, intravascular life, and after extravasation into tissues.
Most dendritic cells are considered to be of hematopoietic lineage" and are derived from CD34' bone marrow stem cell^.'"^^^ There is also a close relationship between CD83' dendritic cells and cells of the myelomonocytic lineage. Morphologically, phenotypically, and functionally mature CD83' dendritic cells can be generated directly from CD14' blood monocytes.*' Therefore, it was not surprising that cells with a dendritic morphology within tonsil, lymph node, spleen, and epidermis expressed PSGL-I. In addition, circulating CD83' dendritic cells expressed PSGL-I (Fig 3A) . We also showed that some CD83+ blood dendritic cells bound Pselectin and that binding was abolished by the anti-PSGL-1 MoAb PLI, but not by PL2. These results indicate that PSGL-1 is the predominant high-affinity ligand for P-selectin on these cells. CD83+ dendritic cells generated from CD14' blood monocytes also expressed PSGL-l that was capable of specifically binding P-selectin (Fig 3B) . Because dendritic cells are highly mobile cells that circulate between blood, peripheral tissues such as skin, the lymphatics, and secondary lymphoid tissues, PSGL-I could be involved in their recruitment to sites of antigen exposure and inflammation. Although the homing patterns of this rare cell type have not been well characterized, dendritic cells express a large array of' adhesion molecules that could facilitate trafficking throughout the body.I6 Of equal interest was the finding that FDCs also expressed PSGL-l . Although the origin of FDCs remains unknown, PSGL-l expression was rather pronounced on these cells, whereas most germinal center and mantle zone lymphocytes were negative. The expression of PSGL-I by FDCs is difficult to interpret based on our limited understanding of the origin and lineage of these cells.
Flow cytometric analysis of thymocytes and immunohistochemical staining of fetal thymus indicated that PSGL-I was expressed on immature and mature thymocytes. PSGL-1 was also present on all subpopulations of peripheral blood lymphocytes examined. Specifically, PSGL-I was present on most, if not all, naive and memory T cells, ylb T cells, For personal use only. on November 11, 2017. by guest www.bloodjournal.org From and NK cells. Although most peripheral blood lymphocytes express the PSGL-1 polypeptide, only a small fraction bind P-selectin with high affinity/avidity.2.'3.34 Binding of P-selectin to this subset of lymphocytes, which are predominantly memory T cells, is PSGL-I -dependent.2s'3.'4 Preferential binding of P-selectin to memory T cells is not due to differential expression of the PSGL-l polypeptide, because PSGL-1 was present at comparable levels on naive and memory T cells. PSGL-1 expression was substantially lower on T cells from tonsils than on T cells from peripheral blood, a finding consistent with the weak staining of lymphocytes in the Tcell zones of secondary lymphoid tissue, as assessed by immunohistochemistry. Thus, PSGL-l is expressed on thymocytes and all circulating T cells. However, our findings indicate that T cells downregulate PSGL-I expression during or after extravasation into secondary lymphoid tissue in vivo.
We have not examined PSGL-1 expression during B-cell development. However, peripheral blood B cells only weakly expressed PSGL-I, in comparison to T and NK cells. Furthermore, PSGL-l expression was lower on B cells isolated from tonsils, consistent with the lack of detectable PSGL-l antigen on follicular lymphocytes in lymph node or tonsils, as assessed by immunohistochemistry.
The only normal nonhematopoietic tissue that consistently stained with the anti-PSGL-l MoAbs was the epithelial lining of the fallopian tube. In fibrocystic disease of the breast, some cysts were also stained. We observed staining of endothelial cells of some small venules and capillaries in pathologic tissues such as benign hyperplasia of the prostate and fibrocystic disease of the breast. However, staining of blood vessels was not detected in a variety of other normal tissues or in tissues undergoing acute inflammation. The data suggest that PSGL-1 is present in some nonhematopoietic tissues in which it may have functions other than mediating leukocyte adhesion. Although these results suggest that PSGL-1 is not expressed in most nonhematopoietic tissues, we cannot exclude the possibility that PSGL-1 is expressed in some tissues at levels below the detection limit of the assay. However, the lack of detectable PSGL-1 immunoreactivity in the parenchyma of most tissues using two different anti-PSGL-1 MoAbs contrasts with the strong PSGL-1 staining of tissue macrophages in those tissues.
Thus, if PSGL-l is expressed in these tissues, it must be expressed at substantially lower levels than on cells of hematopoietic origin.
In summary, our findings show that PSGL-I is largely, but not exclusively, restricted to cells of hematopoietic origin in normal human tissues. It is broadly expressed on differentiating and mature cells in the myeloid, lymphoid, and dendritic lineage. However, PSGL-1 was detected in some nonhematopoietic cells in both normal and pathologic tissues. Further studies are required to determine whether PSGL-1 is synthesized in situ in these tissues and to explore the possible function(s) of PSGL-1 in these cells.
